Q2-2020 Dynamk Life Science Industrials Insights: Trends, Transactions & Headlines

M&A Activity

In This Report

Q2-2020 M&A.jpg
  • M&A

  • Top Headlines

  • LSI VC Investments

  • Dynamk Insights & Recommended Reads

Danaher's acquisition of GE Biopharma ($21.4B) was an outlier and major contributor to Q1 total, followed by Catalent acquisition of MaSTherCell ($315M).  Sartorius acquisition of select Danaher GE Biopharma assets ($825M) was the major M&A deal for Q2. 

Top Headlines

Sartorius Closes Acquisition of Select Assets of Danaher Life Sciences

"The acquisition of this portfolio is a further milestone for Sartorius. The assets we purchased are an excellent strategic and operational fit with both our divisions" said Sartorius Executive Board Chairman and CEO Dr. Joachim Kreuzburg.  Sartorius paid a purchase price of $825M USD.

Venture & Growth Investing in Life Science Industrials

Q2-2020 VC total.jpg

VC and growth investing remains strong in Q2 with tailwinds prevailing.  For example, MGI Tech raised a large Series B  ($1B) to boost production of COVID-related test equipment which contributed significantly to Q2 totals.

Continued early and late stage deployments in Q2 demonstrate overall confidence in Life Science Industrials and strong fundamentals for market growth drivers. Early stage VC investment was a significant contributor to greater capital raised in Life Science Industrials in Q2.

Dynamk Insights & Recommended Reads

The impact of the pandemic on investment activity and investment pace has been top of mind for many. From disruption of clinical trials to conducting all meetings virtually, the number of changes to typical processes have been significant. Yet the industry has proven to be quite adaptable and the outlook for Life Science Industrials remains positive driven in part by an increased demand for biopharma tools, tech, and services. We've gathered a number of interesting resources that provide additional insight:

Business

Manufacturing

Process

Research